Vanguard Global Advisers
NKTR icon

Vanguard Global Advisers’s Nektar Therapeutics NKTR Stock Holding History

Vanguard Global Advisers’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$915K Buy
13,104
+1,850
+16% +$135K ﹤0.01% 1802
2026
Q1 		$810K Buy
+11,254
New +$641K ﹤0.01% 1770

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's NKTR Position: Q2 2026 in Review

Vanguard Global Advisers increased its Nektar Therapeutics (NKTR) stake by 16% in Q2 2026, buying an estimated $135K and bringing the position to 13,104 shares worth $915K. The position accounts for ﹤0.01% of the portfolio, ranked #1802.

Vanguard Global Advisers first reported a position in NKTR in Q1 2026 and has held it in 2 quarters since. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Vanguard Global Advisers held 13,104 shares of Nektar Therapeutics worth $915K as of Q2 2026.
  • Vanguard Global Advisers bought 1,850 Nektar Therapeutics shares in Q2 2026, an estimated $135K.
  • Nektar Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1802 holding.
  • Vanguard Global Advisers first reported a position in Nektar Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.